PL3716979T3 - Połączenie pochodnej 4-pirymidynosulfamidu z inhibitorem sglt-2 do leczenia chorób związanych w endoteliną - Google Patents
Połączenie pochodnej 4-pirymidynosulfamidu z inhibitorem sglt-2 do leczenia chorób związanych w endotelinąInfo
- Publication number
- PL3716979T3 PL3716979T3 PL18814821.7T PL18814821T PL3716979T3 PL 3716979 T3 PL3716979 T3 PL 3716979T3 PL 18814821 T PL18814821 T PL 18814821T PL 3716979 T3 PL3716979 T3 PL 3716979T3
- Authority
- PL
- Poland
- Prior art keywords
- sglt
- inhibitor
- treatment
- combination
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017081050 | 2017-11-30 | ||
| PCT/EP2018/082947 WO2019106066A1 (en) | 2017-11-30 | 2018-11-29 | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3716979T3 true PL3716979T3 (pl) | 2025-08-04 |
Family
ID=64606962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18814821.7T PL3716979T3 (pl) | 2017-11-30 | 2018-11-29 | Połączenie pochodnej 4-pirymidynosulfamidu z inhibitorem sglt-2 do leczenia chorób związanych w endoteliną |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12144811B2 (pl) |
| EP (1) | EP3716979B1 (pl) |
| JP (2) | JP7404235B2 (pl) |
| KR (1) | KR20200094187A (pl) |
| CN (1) | CN111405899B (pl) |
| AU (1) | AU2018376263B2 (pl) |
| BR (1) | BR112020010831A2 (pl) |
| CA (1) | CA3083327A1 (pl) |
| CL (1) | CL2020001394A1 (pl) |
| DK (1) | DK3716979T3 (pl) |
| EA (1) | EA202091324A1 (pl) |
| ES (1) | ES3035734T3 (pl) |
| FI (1) | FI3716979T3 (pl) |
| HR (1) | HRP20250732T1 (pl) |
| HU (1) | HUE071739T2 (pl) |
| IL (1) | IL274943B2 (pl) |
| LT (1) | LT3716979T (pl) |
| MA (1) | MA51203A (pl) |
| MX (1) | MX2020005543A (pl) |
| MY (1) | MY210547A (pl) |
| PH (1) | PH12020550745A1 (pl) |
| PL (1) | PL3716979T3 (pl) |
| PT (1) | PT3716979T (pl) |
| RS (1) | RS66980B1 (pl) |
| SG (1) | SG11202004862XA (pl) |
| SI (1) | SI3716979T1 (pl) |
| TW (1) | TWI809009B (pl) |
| UA (1) | UA127083C2 (pl) |
| WO (1) | WO2019106066A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3658140T (lt) | 2017-02-27 | 2025-08-25 | Idorsia Pharmaceuticals Ltd | Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui |
| WO2018231702A1 (en) | 2017-06-13 | 2018-12-20 | The Regents Of The University Of California | Methods of improving cell-based therapy |
| EP4056182A1 (en) * | 2019-11-07 | 2022-09-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of aprocitentan, preparation method therefor and use thereof |
| CA3156136A1 (en) * | 2019-11-07 | 2021-05-14 | Michael Hadd | Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals |
| BR112022010098A2 (pt) * | 2019-11-26 | 2022-09-06 | Actelion Pharmaceuticals Ltd | Composição farmacêutica para o tratamento de doença vascular pulmonar e/ou disfunção cardíaca em pacientes submetidos à cirurgia de fontan |
| WO2021126977A1 (en) | 2019-12-17 | 2021-06-24 | Chinook Therapeutics, Inc. | Methods of treating iga nephropathy with atrasentan |
| US11730735B2 (en) * | 2020-07-10 | 2023-08-22 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases |
| LT4188389T (lt) * | 2020-07-27 | 2025-11-10 | Dapagliflozinas, skirtas panaudoti taikant lėtinės inkstų ligos gydymo būdą | |
| PT4188389T (pt) | 2020-07-27 | 2025-10-07 | Astrazeneca Ab | Dapagliflozina para utilização em métodos de tratamento de doença renal crónica |
| CN114644595A (zh) * | 2020-12-19 | 2022-06-21 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的无定型态、其药物组合物和用途 |
| WO2023033483A1 (ko) * | 2021-09-02 | 2023-03-09 | 주식회사 대웅테라퓨틱스 | Sglt-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물 |
| JP7396579B2 (ja) * | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
| WO2023227490A1 (en) | 2022-05-22 | 2023-11-30 | Idorsia Pharmaceuticals Ltd | Aprocitentan for the treatment of hypertension |
| CA3251318A1 (en) | 2022-05-25 | 2023-11-30 | Idorsia Pharmaceuticals Ltd | CRYSTALLINE FORMS OF (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL) SODIUM AMIDE |
| JP2025537256A (ja) * | 2022-11-10 | 2025-11-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンジオポエチン様３（ａｎｇｐｔｌ３）阻害剤と溶質担体ファミリー５メンバー２（ｓｌｃ５ａ２）阻害剤の組み合わせによる腎疾患の治療 |
| WO2024136184A1 (ko) * | 2022-12-20 | 2024-06-27 | 주식회사 티에치팜 | 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 경구용 약학 제제 |
| WO2025089933A1 (ko) * | 2023-10-24 | 2025-05-01 | 주식회사 레드엔비아 | Sglt-2 저해제 및 dpp-4 저해제를 포함하는 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| BRPI0116237B8 (pt) | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
| RU2317302C2 (ru) | 2000-12-28 | 2008-02-20 | Киссеи Фармасьютикал Ко., Лтд. | Производные глюкопиранозилоксипиразола и их применение в лекарственных средствах |
| DE60237580D1 (de) | 2001-02-27 | 2010-10-21 | Kissei Pharmaceutical | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| RS53365B (sr) | 2003-08-01 | 2014-10-31 | Mitsubishi Tanabe Pharma Corporation | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma |
| UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
| PL381247A1 (pl) | 2004-03-04 | 2007-05-14 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze |
| CN103467423B (zh) | 2004-03-16 | 2016-03-16 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| WO2007146900A2 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| PE20120542A1 (es) | 2006-06-27 | 2012-05-14 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| MX2010001837A (es) * | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| WO2010023594A1 (en) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| US8685934B2 (en) * | 2009-05-27 | 2014-04-01 | Bristol-Myers Squibb Company | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
| CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| SI2986304T1 (sl) * | 2013-04-18 | 2022-04-29 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe |
| US20160339047A1 (en) | 2014-01-31 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| EP2907811A1 (en) | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| WO2015139386A1 (zh) * | 2014-03-19 | 2015-09-24 | 杭州普晒医药科技有限公司 | 坎格列净一水合物及其晶型、它们的制备方法和用途 |
| CN106132949A (zh) * | 2014-04-04 | 2016-11-16 | 赛诺菲 | 作为治疗糖尿病、肥胖、血脂障碍及相关病症的gpr119调节剂的取代的茚满酮化合物 |
| US20170135981A1 (en) | 2014-05-16 | 2017-05-18 | Astrazeneca Ab | Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor |
| EP3215138A4 (en) | 2014-11-07 | 2018-11-21 | AbbVie Inc. | Methods of treating ckd using predictors of fluid retention |
| WO2017064679A1 (en) | 2015-10-15 | 2017-04-20 | Lupin Limited | Process for the preparation of amorphous canagliflozin |
| LT3658140T (lt) | 2017-02-27 | 2025-08-25 | Idorsia Pharmaceuticals Ltd | Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui |
-
2018
- 2018-11-29 PL PL18814821.7T patent/PL3716979T3/pl unknown
- 2018-11-29 CN CN201880076562.0A patent/CN111405899B/zh active Active
- 2018-11-29 LT LTEPPCT/EP2018/082947T patent/LT3716979T/lt unknown
- 2018-11-29 HR HRP20250732TT patent/HRP20250732T1/hr unknown
- 2018-11-29 MA MA051203A patent/MA51203A/fr unknown
- 2018-11-29 IL IL274943A patent/IL274943B2/en unknown
- 2018-11-29 EA EA202091324A patent/EA202091324A1/ru unknown
- 2018-11-29 TW TW107142595A patent/TWI809009B/zh active
- 2018-11-29 EP EP18814821.7A patent/EP3716979B1/en active Active
- 2018-11-29 DK DK18814821.7T patent/DK3716979T3/da active
- 2018-11-29 WO PCT/EP2018/082947 patent/WO2019106066A1/en not_active Ceased
- 2018-11-29 ES ES18814821T patent/ES3035734T3/es active Active
- 2018-11-29 US US16/768,604 patent/US12144811B2/en active Active
- 2018-11-29 KR KR1020207018658A patent/KR20200094187A/ko not_active Ceased
- 2018-11-29 BR BR112020010831-6A patent/BR112020010831A2/pt unknown
- 2018-11-29 CA CA3083327A patent/CA3083327A1/en active Pending
- 2018-11-29 SG SG11202004862XA patent/SG11202004862XA/en unknown
- 2018-11-29 SI SI201831245T patent/SI3716979T1/sl unknown
- 2018-11-29 RS RS20250663A patent/RS66980B1/sr unknown
- 2018-11-29 MX MX2020005543A patent/MX2020005543A/es unknown
- 2018-11-29 MY MYPI2020002671A patent/MY210547A/en unknown
- 2018-11-29 UA UAA202003789A patent/UA127083C2/uk unknown
- 2018-11-29 FI FIEP18814821.7T patent/FI3716979T3/fi active
- 2018-11-29 HU HUE18814821A patent/HUE071739T2/hu unknown
- 2018-11-29 JP JP2020529550A patent/JP7404235B2/ja active Active
- 2018-11-29 PT PT188148217T patent/PT3716979T/pt unknown
- 2018-11-29 AU AU2018376263A patent/AU2018376263B2/en active Active
-
2020
- 2020-05-27 CL CL2020001394A patent/CL2020001394A1/es unknown
- 2020-05-29 PH PH12020550745A patent/PH12020550745A1/en unknown
-
2023
- 2023-12-13 JP JP2023209979A patent/JP7635355B2/ja active Active
-
2024
- 2024-10-28 US US18/929,609 patent/US20250120973A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274943A (en) | Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases | |
| EP3632494A4 (en) | CATHETER | |
| ZA201703003B (en) | Heparan sulfate biosynthesis inhibitors for the treatment of diseases | |
| EP3256218A4 (en) | Kdm1a inhibitors for the treatment of disease | |
| EP3626298A4 (en) | CATHETER | |
| GB201804255D0 (en) | Macrophage-based therapy | |
| CA186425S (en) | Catheter | |
| GB201813986D0 (en) | Coffins | |
| EP3679976A4 (en) | CATHETER | |
| GB201819853D0 (en) | Therapy | |
| EP3646915B8 (en) | Catheter | |
| EP3662954A4 (en) | CATHETER | |
| PT3770162T (pt) | Derivados de di-hidrocromeno | |
| EP3646914A4 (en) | CATHETER | |
| SG11202006837XA (en) | Dihydroindolizinone derivative | |
| EP3613459A4 (en) | CATHETER | |
| EP3613460A4 (en) | CATHETER | |
| IL274415A (en) | Combined treatments with EZH2 inhibitors | |
| CA187131S (en) | Casket | |
| CA186424S (en) | Catheter | |
| GB201820022D0 (en) | Sterilisation | |
| GB201817385D0 (en) | Therapy | |
| HK40112215A (zh) | 用於c3抑制的组合疗法 | |
| HK40117187A (zh) | 使用htcp抑制剂的疗法 | |
| GB2573210B (en) | Casket |